Millions of older Americans suffering from insomnia regularly use prescription sleep medications, despite the risk of serious side effects-such as falls, broken bones, cognitive impairment and ...

The Food and Drug Administration on Friday approved Eli Lilly's weight-loss drug Zepbound as a treatment for moderate-to-severe sleep apnea and obesity. Zepbound is the first medication approved to ...

The Food and Drug Administration has approved Zepbound, a GLP-1 weight-loss drug from Eli Lilly & Co., for the treatment of moderate to severe sleep apnea certain patients with obesity. Photo courtesy ...

When you want to sleep, you go to bed, lie down, and close your eyes. Simple, right? Well, not quite. For many, this is a luxury they cannot afford. Global data shows that one in every six adults ...

For adults over the age of 65, higher levels of both insomnia symptoms and sleep medication use were associated with higher risk of disability a year later, according to a new study. Insomnia is a ...

Middle-aged adults and seniors would age more gracefully -- and save a few bucks -- if they lay off prescription sleep medications, a new study says. Avoiding sleep drugs would reduce older Americans' ...

Tirzepatide (Zepbound; Eli Lilly) is now approved for the treatment of moderate-to-severe obstructive sleep apnea (OSA) with obesity, the Food and Drug Administration announced late last week. The ...

Sleep patterns, needs, and challenges change throughout your life. Learn more about how sleep evolves with age.

Apnimed has scored another phase 3 knockout. The Massachusetts biotech’s daily pill for obstructive sleep apnea (OSA) reduced the number of nightly breath-stopping events by 46.8%, smashing the ...

The Food and Drug Administration (FDA) approved a weight-loss drug to help sleep apnea, becoming the first drug to treat the disorder affecting millions of Americans. On Friday, the federal agency ...